- Home
- ABSI vs RAPT Comparison
ABSI vs RAPT Comparison
Compare ABSI & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- RAPT
- Stock Information
- Founded
- ABSI 2011
- RAPT 2015
- Country
- ABSI United States
- RAPT United States
- Employees
- ABSI N/A
- RAPT N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- RAPT Health Care
- Exchange
- ABSI Nasdaq
- RAPT Nasdaq
- Market Cap
- ABSI 505.4M
- RAPT 498.4M
- IPO Year
- ABSI 2021
- RAPT 2019
- Fundamental
- Price
- ABSI $4.53
- RAPT $29.34
- Analyst Decision
- ABSI Strong Buy
- RAPT Buy
- Analyst Count
- ABSI 6
- RAPT 8
- Target Price
- ABSI $7.98
- RAPT $35.13
- AVG Volume (30 Days)
- ABSI 7.2M
- RAPT 303.3K
- Earning Date
- ABSI 11-11-2025
- RAPT 11-11-2025
- Dividend Yield
- ABSI N/A
- RAPT N/A
- EPS Growth
- ABSI N/A
- RAPT N/A
- EPS
- ABSI N/A
- RAPT N/A
- Revenue
- ABSI $4,138,000.00
- RAPT N/A
- Revenue This Year
- ABSI $32.44
- RAPT N/A
- Revenue Next Year
- ABSI $359.77
- RAPT N/A
- P/E Ratio
- ABSI N/A
- RAPT N/A
- Revenue Growth
- ABSI 27.32
- RAPT N/A
- 52 Week Low
- ABSI $2.01
- RAPT $5.67
- 52 Week High
- ABSI $6.33
- RAPT $32.35
- Technical
- Relative Strength Index (RSI)
- ABSI 64.46
- RAPT 67.42
- Support Level
- ABSI $3.45
- RAPT $24.25
- Resistance Level
- ABSI $5.23
- RAPT $30.93
- Average True Range (ATR)
- ABSI 0.42
- RAPT 2.71
- MACD
- ABSI 0.12
- RAPT -0.48
- Stochastic Oscillator
- ABSI 67.50
- RAPT 61.11
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.